Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:EGLT

Egalet (EGLT) Stock Price, News & Analysis

Egalet logo

About Egalet Stock (NASDAQ:EGLT)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.0080
$0.0080
50-Day Range
$0.01
$0.33
52-Week Range
$0.03
$1.57
Volume
N/A
Average Volume
853,425 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.

Remove Ads
Receive EGLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Egalet and its competitors with MarketBeat's FREE daily newsletter.

EGLT Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

EGLT Stock Analysis - Frequently Asked Questions

Egalet (NASDAQ:EGLT) released its quarterly earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.06. The specialty pharmaceutical company had revenue of $7.44 million for the quarter, compared to analyst estimates of $8.64 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Egalet investors own include Novavax (NVAX), Palo Alto Networks (PANW), Cara Therapeutics (CARA), TG Therapeutics (TGTX), Ocular Therapeutix (OCUL), Trevena (TRVN) and 22nd Century Group (XXII).

Company Calendar

Last Earnings
8/08/2018
Today
3/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EGLT
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:EGLT) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners